• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 19, 2012

View Archived Issues

ThromboGenics Sets January Launch as FDA Approves Jetrea

In an eagerly awaited milestone for the company – and for Belgian biotech – the FDA approved ThromboGenics NV's biologic drug Jetrea (ocriplasmin) for treating symptomatic vitreomacular adhesion (VMA). Read More

Yes and No: FDA Panel Votes Shyly in Favor of Mipomersen

Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH) overcame testimony about liver problems, cancer in mice, possible cardiac risk, troubling immune responses and significant trial dropout rates to win a vote recommending approval from an FDA advisory panel. Read More

BioCryst, Presidio in All-Stock Deal; Form HCV Powerhouse

BioCryst Pharmaceuticals Inc., of Research Triangle Park, N.C., will acquire Presidio Pharmaceuticals Inc., of San Francisco, in an all-stock transaction valued at about $101 million, creating a new company centered on hepatitis C virus (HCV) and rare disease hereditary angioedema (HAE). Read More

Safety Halts Reata's CKD Trial of Abbott-Partnered AIM Drug

Reata Pharmaceuticals Inc. ended a Phase III trial testing bardoxolone methyl in patients with Stage IV chronic kidney disease (CKD) and Type II diabetes after the independent data monitoring committee (IDMC) pointed to safety signals in the treatment arm, halting development of a drug that had once been hailed a potential blockbuster. Read More

Other News To Note

• Cleveland BioLabs Inc., of Buffalo, N.Y., said it submitted a proposal to the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services for funding to complete the development steps needed for FDA licensure of Entolimod as a medical radiation countermeasure. Read More

Pharma: Other News To Note

• Sanofi Pasteur, of Swiftwater, Pa., the vaccines division of Sanofi SA, said it filed a supplemental biologics license application for a quadrivalent formulation of its Fluzone (influenza virus vaccine). The filing was accepted by the FDA for full review, and an action date is anticipated in the second quarter of 2013. Read More

Pharma: Clinic Roundup

• Janssen Research & Development LLC, of Spring House, Pa., a unit of Johnson & Johnson, said a Phase IIb study testing Stelara (ustekinumab) in moderate to severe Crohn's disease showed that, among patients who had previously failed or were intolerant to at least one tumor necrosis factor antagonist, a significantly greater proportion receiving intravenous Stelara achieved the primary endpoint of clinical response at week six, defined as a 100-point reduction in Crohn's Disease Activity Index, compared to patients receiving placebo (40 percent vs. 24 percent). Read More

Clinic Roundup

• Novavax Inc., of Rockville, Md., said top-line results from two Phase I trials of its A/H5N1 avian influenza vaccine candidate showed that the vaccine is safe and produces immunogenicity with and without adjuvant. It also showed statistically significant adjuvant effects on immune responses. Read More

Financings Roundup

• Provectus Pharmaceuticals Inc., of Knoxville, Tenn., said it terminated its proposed convertible preferred stock offering due to current market conditions. The company, which is developing cancer drug PV-10, had filed a preliminary prospectus supplement in September. Shares of Provectus (NASDAQ:PVCT) gained 12 cents, or 23 percent, to close Thursday at 65 cents. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe